Pengpeng Sun1, Yunfei Zhang2, Kaicheng Li1, Cong Wang3, Feng Zeng3, Jinyu Zhu1, Yongming Dai2, Xiaofeng Tao1, and Yinwei Wu1
1Shanghai Ninth People’s Hospital, Shanghai, China, 2United Imaging Healthcare, Shanghai, China, 3Fudan University, Shanghai, China
Synopsis
Accurately defining infiltrative
tumor margin is extremely crucial for complete resection and avoiding mistaken
removal of normal tissue. Currently, pre-operative MRI
imaging is the most widely-used strategy for defining tumor margin. However, there are plenty of
insurmountable disadvantages in terms of accuracy, low resolution, mismatch and
so on. This research aims to develop one targeting MRI-Raman nanoprobe able to
pre-operatively and intra-operatively evaluate infiltrative margin of head and neck
carcinoma (HNSCC) and real-timely guide tumor resection. The results showed
that the nanoprobe greatly benefits the complete resection of HNSCC. As a
result, the prognosis of tumor-bearing rabbits were considerably improved.
Introduction
As the infiltrative character of many tumors can notoriously lead to a lot of clinical outcomes including the recurrence, poor prognosis and so on. Accurate defining the infiltrative margin that is extremely crucial for thorough surgical resection as well as preventing the mistaken removal of normal tissue has gained the attention of innumerable researchers.1-4 During the clinical practice, the pre-operative MRI imaging, with a lot of insurmountable weaknesses containing low resolution, low sensitivity, mismatch, unsatisfied accuracy and so on, is the most widely-used strategy for defining tumor margin. Having the priorities being complementary to MRI such as ultra-high sensitivity , multiplexing capability sourced from fingerprint-like spectrum and more, Raman Imaging has recently displayed fascinating clinical potential in intra-operatively guiding tumor resection.5 However, as far as we are aware, Raman imaging was hardly applied in combination with MRI for defining the infiltrative tumor margin of HNSCC. This research aims to develop one multiple model–MR-Raman targeting nanoprobe to improve surgical resection of HNSCCs (Figure 1).Methods
Synthesis and Characterization: The gold nanostar
(AuS) based multiple model nanoprobe termed as AuS-Cy7-Gd was synthesized according to our previous work.1 DTPA-Gd
was fabricated on the surface of gold nanostar for serving as MRI reporters.
Cy7-SH is a type of heptamethine cyanine molecule, which was
applied for serving as Raman reporter.
Establishment of VX2 Tumour bearing rabbit Modal: VX2 tumour models were established according to our previous study.1
Pre-operatively imaging infiltrative tumor margin of HNSCC: MR measurements was performed with the 3-T MR scanner (MAGNETOM Verio,
Siemens AG, Germany). The main protocol includes both pre- and post-contrast
coronal T1-weighted imaging (T1WI). The detailed parameters are as followings:
FOV: 120×120 mm2, matrix: 256×160, TR/TE: 350/15 ms, slice
thickness: 1.0 mm, NEX: 2. The contrast-enhanced T1WI image was obtained 20 min
post-intravenous administration of AuS-Cy7-Gd via the
ear vein. The T1 relaxation rate of nanoprobe was measured with 1.5 T MR
scanner (uMR560, Shanghai United Imaging Healthcare, China).
Intra-operatively guiding
HNSCC resection with the aid
of targeting nanoprobe:
All of the HNSCC bearing rabbits were randomly
divided into two groups (n = 10 for each group) as follows: (1) the
nanoprobe-guided tumour surgery group, referring to the group where intraoperative
Raman guided surgical resection of primary tumour; and (2) the
white-light-illumination surgery group, referring to the group for which tumour
resection was performed only under white-light illumination but without Raman
imaging guidance; Results
The
multifunctional MRI-Raman nanoprobe developed in this work, termed as
AuS-Cy7-Gd, had an average diameter of 60 nm. The synthesis of the nanoprobe is
described in Figure 2.
Preoperative
MR Delineation of infiltrative
margins:
Prior
to administration AuS-Cy7-Gd, the tumour margins were blurred and could not be
well defined on the T1WI MR images (Figure
3). In addition to the primary tumour, an enlarged homolateral lymph node
was visualized on the right side of the neck, with heterogeneous
hypo-intensities. Compared to the pre-contrast images, an obvious enhancement
(80% increase of normalized SI) of the tumour marginal areas delineated the
primary tumour more clearly on contrast-enhanced T1WI images, and infiltrative
margins of the tumour were observed with contrast enhancement (Figure 3).
Intraoperative Raman delineation of infiltrative
margins:
Figure 4 illustrates the step-by-step Raman-guided surgical resection procedures.
Corresponding Raman spectrum (panel B) of the illuminated area was synergized
in the Raman-guided surgical resection process (panel A). Characteristic double
Raman peaks at 509 cm-1 and 541 cm-1 were observed in
tumour areas, representing the AuS-Cy7-Gd’s accurate targeting in the infiltrative
tumor margin. Figure 5 illustrated that AuS-Cy7-Gd was able to accurately
visualize the infiltrative tumor margin and improve the surgical prognosis of
HNCSS bearing rabbit model.Discussion
Based
on Enhanced permeability and retention (EPR) effect6, with diameter of around 60 nm, the MR-Raman
nanoprobe – AuS-Cy7-Gd can accurately target into tumor tissue especially in
infiltrative tumor margin with strong angiogenesis effect, which endowed the
AuS-Cy7-Gd with the ability of depicting the infiltrative tumor margin of
HNSCCs. Moreover, with the MR reporters (Gd3+) and Raman reporters
(Cy7-SH) fabricated on AuS surface, the AuS-Cy7-Gd can both help preoperatively
imaging infiltrative tumor margin and intraoperatively guiding tumor resection
with fingerprint-like spectrum of Cy7-SH (509 cm-1 and 543 cm-1).
In the preoperative evaluation, the obvious enhancement in T1WI images provided
the preliminary characterization of infiltrative tumor margin. Furthermore,
accurately targeting into tumor tissue especially in tumor margin, the
characteristic Raman signal of 509 cm-1 and 543 cm-1 of nanoprobe
suggested the malignant lesions and infiltrative margins. Most importantly,
according to the preoperative and intraoperative guidance sourced from MR-Raman
multiple model nanoprobe–AuS-Cy7-Gd, much more clear delineation of tumor
margin was achieved, which greatly improved the prognosis of tumor-bearing
rabbit model compared to prognosis of tumor bearing rabbit without the guidance
of nanoprobe.Conclusion
Overall,
the bimodal MR-Raman probe with high targeting capability developed in this
study enabled intraoperative visualization and image-guided resection of
HNSCCs. The high sensitivity and tumour specificity between preoperative and intraoperative
images of MRI and Raman imaging provide a new opportunity to improve the
surgical prognosis of tumours with infiltrative behaviour.Acknowledgements
No AcknowledgementsReferences
1. Han L, Duan W, Li X, et
al. Surface-Enhanced Resonance Raman Scattering-Guided Brain Tumor Surgery
Showing Prognostic Benefit in Rat Models. ACS Appl Mater Inter 2019;11(17):15241-15250.
2. Crombe
A, Le Loarer F, Stoeckle E, et al. MRI assessment of surrounding tissues in
soft-tissue sarcoma during neoadjuvant chemotherapy can help predicting
response and prognosis. Eur J Radiol 2018;109:178-187.
3. Iwata
S, Araki A, Funatsu H, et al. Optimal surgical margin for
infiltrative soft tissue sarcomas: Assessing the efficacy of excising beyond
the infiltration. J Surg Oncol 2018;118(3):525-531.
4. Peeken
JC, Molina-Romero M, Diehl C, et al. Deep learning derived tumor infiltration
maps for personalized target definition in Glioblastoma radiotherapy.
Radiotherapy and oncology : journal of the European Society for Therapeutic
Radiology and Oncology 2019;138:166-172.
5. Karabeber
H, Huang R, Iacono P, et al. Guiding brain tumor resection using
surface-enhanced Raman scattering nanoparticles and a hand-held Raman scanner.
ACS Nano 2014;8(10):9755-9766.
6. Maeda
H, Nakamura H, Fang J. The EPR effect for macromolecular drug delivery to solid
tumors: Improvement of tumor uptake, lowering of systemic toxicity, and
distinct tumor imaging in vivo. Adv Drug Deliv Rev 2013;65(1):71-79.